The U.S. Food and Drug Administration approved mFlusiva on Wednesday, marking the country’s first messenger RNA influenza vaccine. Developed by Moderna, the shot is authorized for adults aged 50 and older and is slated to be available for the fall vaccination season.
The authorization introduces a prominent alternative to traditional egg- and cell-based flu shots, bringing the mRNA technology used in COVID-19 vaccines into seasonal influenza prevention. The approval covers two distinct adult populations under different regulatory pathways following an unusual internal dispute earlier this year.
Regulatory Approval and Age-Specific Trial Data
For adults aged 50 to 64, the agency granted full approval based on a late-stage clinical trial tracking 40,805 adults across 11 countries. Data presented to the FDA showed that trial participants in this demographic who received mFlusiva were 27 percent less likely to contract test-confirmed influenza compared to those who received a standard-dose comparator vaccine.
For adults aged 65 and older, the FDA granted an accelerated approval based on a smaller study involving nearly 3,000 U.S. adults that demonstrated a strong immune response compared to existing high-dose options. As a condition of the accelerated status, Moderna has agreed to conduct a post-licensure Phase 4 trial to gather additional comparative effectiveness data against existing high-dose or adjuvanted vaccines.
Clinical data showed no major safety concerns, though the mRNA shot caused temporary side effects somewhat more frequently than traditional flu shots. Reported reactions included injection-site pain, fever, headache, tiredness, and aches, which were predominantly mild to moderate and resolved within one to two days.
Manufacturing Speed and Strain Matching
Public health experts have long highlighted the manufacturing limitations of traditional influenza vaccines, which require growing the virus in eggs or cells over roughly a six-month period. That protracted timeline forces the World Health Organization and other advisory committees to select targeted strains months before the flu season begins.
If you’re choosing the strain half a year before, how good can we be at sharpshooting?
said Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children’s Hospital.
Infectious disease specialists note that this speed allows medical experts to adapt more closely if a dominant or unexpected flu strain emerges late.
An Unfolding Dispute and Public Health Reception
The approval process encountered significant friction earlier this year. In February, the agency’s then-head of biologics, Vinay Prasad, issued a rare refusal-to-file notice that blocked the application over testing methodology after overriding career staff recommendations. Following public pushback from Moderna, the agency reversed its position within two weeks, and Prasad departed the FDA at the end of April.
An independent advisory committee to the FDA subsequently voted unanimously in June to recommend approval, concluding that the vaccine’s benefits outweighed any risks. Medical organizations praised the decision as a milestone.
At the same time, public health advocates acknowledge that vaccine skepticism and political headwinds pose challenges for uptake. Kennedy Jr., a vaccine skeptic who oversees the agency, previously canceled nearly $500 million in mRNA vaccine research funding and asserted that mRNA technology poses more risks than benefits for these respiratory viruses.
Despite these hurdles, medical professionals maintain that the authorization broadens the utility of messenger RNA platforms. Science wins out in the end,
said Dr. Paul Offit, director of the vaccine education center and a physician at Children’s Hospital of Philadelphia.
Distribution Hurdles and Commercial Availability
Moderna announced that doses of mFlusiva will be marketed and made available at select retailers for the upcoming autumn vaccination campaign.
Experts note that while mFlusiva can be legally prescribed without ACIP guidance, the lack of formal federal recommendations creates coverage complications. Private insurers generally rely on ACIP guidelines to determine coverage policies, and public programs such as Medicaid and the Vaccines for Children initiative depend on the same federal framework to distribute supplies widely.